Abstract:Abstract Background Bone marrow-derived stromal cells (MSC) are attractive targets for ex vivo cell and gene therapy. In this context, we investigated the feasibility of a plasmid-based strategy for genetic modification of human (h)MSC with enhanced green fluorescent protein (EGFP) and neurotrophin (NT)3. Three genetically modified hMSC lines (EGFP, NT3, NT3-EGFP) were established and used to study cell survival and transgene expression following transplantation in rat spinal cord. Results First, we demonstrate long-term survival of transplanted hMSC-EGFP cells in rat spinal cord under, but not without, appropriate immune suppression. Next, we examined the stability of EGFP or NT3 transgene expression following transplantation of hMSC-EGFP, hMSC-NT3 and hMSC-NT3-EGFP in rat spinal cord. While in vivo EGFP mRNA and protein expression by transplanted hMSC-EGFP cells was readily detectable at different time points post-transplantation, in vivo NT3 mRNA expression by hMSC-NT3 cells and in vivo EGFP protein expression by hMSC-NT3-EGFP cells was, respectively, undetectable or declined rapidly between day 1 and 7 post-transplantation. Further investigation revealed that the observed in vivo decline of EGFP protein expression by hMSC-NT3-EGFP cells: (i) was associated with a decrease in transgenic NT3-EGFP mRNA expression as suggested following laser capture micro-dissection analysis of hMSC-NT3-EGFP cell transplants at day 1 and day 7 post-transplantation, (ii) did not occur when hMSC-NT3-EGFP cells were transplanted subcutaneously, and (iii) was reversed upon re-establishment of hMSC-NT3-EGFP cell cultures at 2 weeks post-transplantation. Finally, because we observed a slowly progressing tumour growth following transplantation of all our hMSC cell transplants, we here demonstrate that omitting immune suppressive therapy is sufficient to prevent further tumour growth and to eradicate malignant xenogeneic cell transplants. Conclusion In this study, we demonstrate that genetically modified hMSC lines can survive in healthy rat spinal cord over at least 3 weeks by using adequate immune suppression and can serve as vehicles for transgene expression. However, before genetically modified hMSC can potentially be used in a clinical setting to treat spinal cord injuries, more research on standardisation of hMSC culture and genetic modification needs to be done in order to prevent tumour formation and transgene silencing in vivo .

Enhanced green fluorescent protein gene-modified human bone marrow stromal cells induced by lentivirus

A Study on Transfecting Green Fluorescent Protein Gene to Rat Bone Marrow Mesenchymal Stem Cells

[Expression of Human VEGF165 Gene in Rat Bone Marrow Stromal Cells in Vitro].

[A Study on Transfection of Green Fluorescence Protein Gene into Human Adipose Stromal Cells in Vitro].

Retrovirus-mediated expression of enhanced green fluorescent protein in rat bone marrow stem cells

Transfection of Enhanced Green Fluorescent Protein Gene into Bone Marrow Mesenchymal Stem Cells

Transfection of rat bone marrow mesenchymal stem cell with green fiuorescent protein by adenovirus vector

Lentivirus-mediated enhanced green fluorescent protein gene transfection in rabbit bone marrow mesenchymal stem cells in vitro

[Enhanced Green Fluorescence Protein Reporter Gene Labeling of Mesenchymal Stem Cells Mediated by Lentivirus].

Experimental study on transfection of adenovirus vector encoding green fluorescent protein into human bone marrow-derived mesenchymal stem cells

Plasmid transfection of rat bone marrow mesenchymal stem cells by cationic lipid for gene-modified cell transplantation therapy]

[Transduction of Recombinant Marrow Stem Cells Using Lentiviral Vector and Adenoviral Vector: a Comparative Study].

[Test of Transient Expression of Green Fluorescent Protein Gene Transferred to Bone Marrow Stromal Cells].

Culture and Identification of Bone Marrow Mesenchymal Stem Cells from Enhanced Green Fluorescent Protein-transgenic Rats.

Effects of lentiviral transfection containing bFGF gene on the biological characteristics of rabbit BMSCs.

Nucleofection of Primary Bone Marrow Stromal Cells of Rabbit with Pegfp-C2

Transfection of green fluorescent protein gene into endothelial progenitor cells derived from bone marrow in vitro

Osteogenic induction of rabbit's bone marrow stromal cells and transfection of AAV-EGFP in vitro

[Mesenchymal Stem Cells Transduced by PLEGFP-N1 Retroviral Vector Maintain Their Biological Features and Differentiation].

Plasmid-based genetic modification of human bone marrow-derived stromal cells: analysis of cell survival and transgene expression after transplantation in rat spinal cord

Nanovector for Gene Transfection and MR Imaging of Mesenchymal Stem Cells.